Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax
Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax
Active, not recruiting · NCT04501939 · Registry updated 2025-09-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2025-09-02 | NCT04501939 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Oncternal Therapeutics, Inc | 1 |
| University of California, San Diego | 337 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| UCSD Koman Family Outpatient Pavilion | San Diego | United States | 1 |